Celltrion Healthcare starts to sell biosimilar ‘Herzuma’ in Japan

Celltrion Healthcare announced on the 23^rd that they would start to sell the antibody biosimilar ‘Herzuma(generic name: trastuzumab)’ this month in Japan. The Japanese Ministry of Health, Labour and Welfare approved ‘Herzuma’ sales last March.

The Japanese trastuzumab market is approximately worth KRW 400 billion, and ‘Herzuma’ will be jointly sold by its Japanese distribution partner ‘NIPPON ...